Lexeo Therapeutics, INC 10-Q quarterly reports

Lexeo Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing clinical trial progress and financial performance, including a net loss of $25.9 million.

Lexeo Therapeutics reported its first-quarter 2026 financial results, highlighting progress in its gene therapy pipeline for cardiovascular diseases and a strong cash position.

Lexeo Therapeutics reports Q3 2025 financial results with increased net losses but significant clinical progress for LX2006 and a substantial post-period capital raise.

Lexeo Therapeutics reported significant clinical progress for its lead gene therapy candidates and bolstered its financial position with a $73.1 million private placement, extending its cash runway into 2028.

Lexeo Therapeutics files an amendment to its Q1 2025 quarterly report to correct language in exhibits related to internal control over financial reporting.

Lexeo Therapeutics announces Q1 2025 financial results, highlighting progress in clinical trials for LX2006 and LX2020, and a strategic capital reallocation.

Lexeo Therapeutics' third quarter 2024 report details ongoing clinical trials, financial status, and strategic developments.

Lexeo Therapeutics, a clinical-stage genetic medicine company, filed its 10-Q report for the quarter ended June 30, 2024, detailing its financial status and operational progress.

Lexeo Therapeutics reports a net loss of $21.7 million for the first quarter of 2024, alongside updates on clinical trials and a recent private placement.